🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Shares

Former Wiggins team mate questions timing of TUEs

Published 07/10/2016, 03:03
© Reuters. Cyclist Bradley Wiggins speaks on the BBC's Andrew Marr Show in this undated photograph received via the BBC in London

LONDON (Reuters) - A former team mate of Bradley Wiggins has called into question the British rider's use of a therapeutic use exemption (TUE) for triamcinolone before his 2012 Tour de France win.

Jonathan Tiernan-Locke, who rode for Team Sky until he was sacked for a doping violation in 2014, was asked about Wiggins' use of the anti-inflammatory drug in a BBC interview.

"I don't want to insinuate anything but the timing doesn't look great," Tiernan-Locke said.

"You assume if you had a need for such a thing it would be consistent throughout his career, that you'd use it year in year out, so from that point of view it looks suspicious."

Wiggins' use of TUEs, which allow athletes to take banned substances for verified medical needs and are signed off by sports federations, was leaked last month by the Russian-based Fancy Bears cyber hacking site.

There is no suggestion of any wrongdoing on the part of five-times Olympic gold medal winner Wiggins who denied looking for any "unfair advantage", saying the medication was to reduce the impact of asthma and allergies.

Team Sky boss Dave Brailsford also defended Wiggins by saying he had suffered from allergies for as long as he had known him and that the team had not "crossed the line".

Tiernan-Locke said that while Sky would have been thorough in their preparation for the Tour de France, the way their use of TUEs was revealed had aroused suspicion.

"People I have spoken to, out of training, it has kind of tainted (Sky's) image somewhat," he said.

"I think their modus operandi was to put things out in the public domain and look transparent and not have anything to hide. It's somewhat less than transparent.

"From the other perspective we've got a guy who's favorite for the general classification in these big races, so for a team like Sky who are so thorough, they don't want to leave anything to chance, so why risk these allergies derailing their best-laid plans, so I understand it."

The data leak also showed Wiggins was given permission to take triamcinolone before the 2011 Tour de France and 2013 Tour of Italy.

© Reuters. Cyclist Bradley Wiggins speaks on the BBC's Andrew Marr Show in this undated photograph received via the BBC in London

On each occasion the TUE was approved by British authorities and cycling's governing body the UCI.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.